Individualized prevention of proton pump inhibitor related adverse events by risk stratification
Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Research
2024
|
| _version_ | 1811140069406277632 |
|---|---|
| author | Xia, B He, Q Smith, FG Gkoutos, VG Nirantharakumar, K Kuo, ZC Wang, D Feng, Q Cheung, EC Dai, L Huang, J Yu, Y Meng, W Qin, X Yuan, J |
| author_facet | Xia, B He, Q Smith, FG Gkoutos, VG Nirantharakumar, K Kuo, ZC Wang, D Feng, Q Cheung, EC Dai, L Huang, J Yu, Y Meng, W Qin, X Yuan, J |
| author_sort | Xia, B |
| collection | OXFORD |
| description | Proton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public. |
| first_indexed | 2024-09-25T04:16:07Z |
| format | Journal article |
| id | oxford-uuid:d62c0be9-eda9-47cc-88c2-b878e3caa612 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:16:07Z |
| publishDate | 2024 |
| publisher | Nature Research |
| record_format | dspace |
| spelling | oxford-uuid:d62c0be9-eda9-47cc-88c2-b878e3caa6122024-07-20T14:48:48ZIndividualized prevention of proton pump inhibitor related adverse events by risk stratificationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d62c0be9-eda9-47cc-88c2-b878e3caa612EnglishJisc Publications RouterNature Research2024Xia, BHe, QSmith, FGGkoutos, VGNirantharakumar, KKuo, ZCWang, DFeng, QCheung, ECDai, LHuang, JYu, YMeng, WQin, XYuan, JProton pump inhibitors (PPIs) are commonly used for gastric acid-related disorders, but their safety profile and risk stratification for high-burden diseases need further investigation. Analyzing over 2 million participants from five prospective cohorts from the US, the UK, and China, we found that PPI use correlated with increased risk of 15 leading global diseases, such as ischemic heart disease, diabetes, respiratory infections, and chronic kidney disease. These associations showed dose-response relationships and consistency across different PPI types. PPI-related absolute risks increased with baseline risks, with approximately 82% of cases occurring in those at the upper 40% of the baseline predicted risk, and only 11.5% of cases occurring in individuals at the lower 50% of the baseline risk. While statistical association does not necessarily imply causation, its potential safety concerns suggest that personalized use of PPIs through risk stratification might guide appropriate decision-making for patients, clinicians, and the public. |
| spellingShingle | Xia, B He, Q Smith, FG Gkoutos, VG Nirantharakumar, K Kuo, ZC Wang, D Feng, Q Cheung, EC Dai, L Huang, J Yu, Y Meng, W Qin, X Yuan, J Individualized prevention of proton pump inhibitor related adverse events by risk stratification |
| title | Individualized prevention of proton pump inhibitor related adverse events by risk stratification |
| title_full | Individualized prevention of proton pump inhibitor related adverse events by risk stratification |
| title_fullStr | Individualized prevention of proton pump inhibitor related adverse events by risk stratification |
| title_full_unstemmed | Individualized prevention of proton pump inhibitor related adverse events by risk stratification |
| title_short | Individualized prevention of proton pump inhibitor related adverse events by risk stratification |
| title_sort | individualized prevention of proton pump inhibitor related adverse events by risk stratification |
| work_keys_str_mv | AT xiab individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT heq individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT smithfg individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT gkoutosvg individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT nirantharakumark individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT kuozc individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT wangd individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT fengq individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT cheungec individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT dail individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT huangj individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT yuy individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT mengw individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT qinx individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification AT yuanj individualizedpreventionofprotonpumpinhibitorrelatedadverseeventsbyriskstratification |